| Literature DB >> 26025459 |
Lucas Y H Goh1, Yiu-Wing Kam2, Stefan W Metz3, Jody Hobson-Peters1, Natalie A Prow1, Suzi McCarthy4, David W Smith4, Gorben P Pijlman3, Lisa F P Ng2, Roy A Hall5.
Abstract
Chikungunya fever (CHIKF) has re-emerged as an arboviral disease that mimics clinical symptoms of other diseases such as dengue, malaria, as well as other alphavirus-related illnesses leading to problems with definitive diagnosis of the infection. Herein we describe the development and evaluation of a sensitive epitope-blocking ELISA (EB-ELISA) capable of specifically detecting anti-chikungunya virus (CHIKV) antibodies in clinical samples. The assay uses a monoclonal antibody (mAb) that binds an epitope on the E2 protein of CHIKV and does not exhibit cross-reactivity to other related alphaviruses. We also demonstrated the use of recombinant CHIK virus-like particles (VLPs) as a safe alternative antigen to infectious virions in the assay. Based on testing of 60 serum samples from patients in the acute or convalescent phase of CHIKV infection, the EB-ELISA provided us with 100% sensitivity, and exhibited 98.5% specificity when Ross River virus (RRV)- or Barmah Forest virus (BFV)-immune serum samples were included. This assay meets the public health demands of a rapid, robust, sensitive and specific, yet simple assay for specifically diagnosing CHIK-infections in humans.Entities:
Keywords: Chikungunya virus; Clinical diagnostic; Epitope-blocking ELISA; Monoclonal antibodies; Virus-like particles
Mesh:
Substances:
Year: 2015 PMID: 26025459 DOI: 10.1016/j.jviromet.2015.05.011
Source DB: PubMed Journal: J Virol Methods ISSN: 0166-0934 Impact factor: 2.014